Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Obesity is a condition of pandemic proportions in the modern world. A myriad of conditions ranging from cardiovascular disease, Type-II diabetes, cancer, and even depression have been linked to obesity.
Research into the mechanisms and treatment of obesity is an ongoing area of interest to many in the pharmaceutical and academic communities. Animal models have proven useful in studying the effects of compounds on diet-induced obesity.
At Melior we utilize a high-fat diet platform to model a number of acute and chronic features of metabolic and obesity disorders consistent with diet-induced obesity changes in humans.
Together these data indicate over time, on a high-fat diet, animals gain bodyweight, primarily fat, and these effects can be attenuated by treatment with rimonabant.
DIO studies can be performed in mice or rats. They are typically about 8 weeks in duration and involve group sizes of about 8-12 animals. In addition to DEXA and bodyweight, other endpoints that are included in the DIO model studies include glycemic control parameters such as fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and/or insulin tolerance test (ITT).